Related Experiment Videos
Clinical trials in crystal arthropathy
Nancy Joseph-Ridge1, Susan Cazzetta, Patricia MacDonald
1TAP Pharmaceutical Products, Inc., Lake Forest, IL, USA. Nancy.joseph-ridge@TAP.com
Rheumatic Diseases Clinics of North America
|May 24, 2006
Summary
Clinical trials for crystal-associated arthropathies are limited, often observational. Newer therapeutic agents show promise for effective and safe long-term management of crystal-induced joint conditions.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Limited clinical trials exist for crystal-associated arthropathies.
- Most current studies are uncontrolled and observational.
- Patient management is typically symptomatic for acute flares, with chronic strategies varying by crystal type.
Purpose of the Study:
- To review current therapeutic agents for crystal-associated arthropathies.
- To highlight the limitations in chronic management, particularly for calcium crystal deposition diseases.
- To discuss emerging treatments showing potential in clinical trials.
Main Methods:
- Review of existing clinical trial data.
- Analysis of management strategies for gout and calcium crystal arthropathies.
- Evaluation of commonly used agents like xanthine oxidase inhibitors and uricosurics.
Main Results:
- Gout trials often prioritize acute symptomatic relief over chronic urate-lowering management.
- Effective long-term treatments for calcium crystal arthropathies remain largely undefined.
- Newer pharmaceutical compounds are demonstrating promising efficacy and safety profiles in ongoing trials.
Conclusions:
- There is a need for more rigorous, controlled clinical trials in crystal-associated arthropathies.
- Novel therapeutic agents may offer improved long-term management options.
- Further research is essential to establish definitive treatments for chronic crystal arthropathies.